Bupivacaine Hydrochloride

Approved

NNorthwestern University

Bupivacaine Hydrochloride is one of 4 therapeutic programs targeting Pain, Postoperative. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pain, PostoperativeEnrolling by invitation

Labor PainRecruiting

Pain, PostoperativePhase 1

Enrolling by invitation

Labor PainApproved

Recruiting

Competition

Competitive Landscape

9 competitors in Pain, Postoperative

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

1 2

Bupivacaine Hydrochloride

NNorthwestern University

Approved

1 3

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Phase 2

1 4

Standard Bupivacaine

TThe University of Hong Kong

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Labor Pain

NCT06146842

ApprovedRecruiting

Labor Pain

NCT05543694

Clinical

Trials by Indication[1]

Labor Pain2 trials

A Trial to Determine the Optimal Bupivacaine Dose for Initiation of Labor Epidural Pain Relief With a Lidocaine Test Dose

Recruiting·BBrigham and Women's Hospital·Approved·NCT06146842·120 enrolled

ED90 of Epidural Bupivacaine for the Initiation of Labor Analgesia: A Randomized Biased Coin Sequential Allocation Trial With a Lidocaine Test Dose

Recruiting·BBrigham and Women's Hospital·Approved·NCT05543694·120 enrolled

Pain, Postoperative1 trial

Locally Administered Bupivacaine Hydrochloride for Post-operative Pain Control in Cutaneous Surgery: A Randomized Controlled Trial

Enrolling by invitation·NNorthwestern University·Phase 1·NCT04260854·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Bupivacaine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bupivacaine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: NNorthwestern University

Bupivacaine Hydrochloride

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Labor Pain2 trials

Pain, Postoperative1 trial

References

Drug Info

Quick Facts

Related News